Deals and Financings Suzhou Innovent Bio and Eli Lilly signed a $1+ billion package giving Lilly exclusive rights to market Tyvyt®, their partnered anti-PD-1, in global markets outside of China; JD Health, the online healthcare arm of China ’s JD.com, will raise more than $830 million from Hillhouse Capital in a Series B financing; Hua Medicine out-licensed China market rights to Bayer AG for its lead type 2 diabetes treatment in a $658 million agreement; JW Therapeutics, a China JV formed by CAR-T specialist Juno and China's WuXi AppTec, filed for a Hong Kong IPO expected to raise up to $300 million; Junshi Bio of Shanghai invested $43 million in a JV to co-develop a PARP inhibitor discovered by Nanjing 's Impact Therapeutics; Beijing Keya Medical Technology closed a $22 million Series B+ funding to support its AI-based cardiovascular imaging software; DK Medtech of Suzhou raised $14 million in a Series B+ round to continue developing its portfolio of balloon catheters; Galixier, a China AI-based company offering drug discovery services, closed a pre-Series A funding of close to $10 million; Ocumension of Shanghai paid $9.5 million to add South Korea rights to its greater China in-licensing agreement with EyePoint Pharma for two eye drugs; Harbour Biomed will collaborate with two Dutch entities to develop a COVID-19 treatment that combines a mAb and Natural Killer cells; Trials and Approvals   Shanghai Henlius Biotech, a Fosun Pharma offspring, has been approved to launch its Herceptin biosimilar in China ; GNI Group, a Japan-China biopharma, reported positive results from a China Phase II clinical trial of a liver fibrosis candidate; Ascletis Pharma of Hangzhou started dosing HBV patients in a China Phase IIa trial of its in-licensed PD-L1 antibody; Shanghai 's I-Mab started a China Phase Ib trial of plonmarlimab, a GM-CSF inhibitor, in patients with rheumatoid arthritis. Stock Symbols: (HK: 01801) Lilly (NYSE: LLY) (HK: 2552) (Xetra: BAYN) (HK: 1877; SHA: 688180) (SHA: 603259; HK: 2359) (NSDQ: EYPT) (HK: 2696) (SHA: 600196; HK: 2196) (TSE Mothers 2160) (HK: 1672) (NSDQ: IMAB) Share this with colleagues: // //